Purpose: This study evaluates the feasibility of lung dose prediction based on target contour and patient anatomy for breast patients treated with proton therapy.
| INTRODUCTION
Radiation dose distribution depends on target size and target location relative to organs at risk. Therefore, it is often difficult to know a priori what the dose to normal tissues for a patient may be achievable. This can make selecting the optimal treatment approach for a specific patient challenging. Being able to predict the dose to normal tissues prior to treatment planning can guide radiation oncologists and physicists toward realistic clinical goals in the planning stage and ensure the quality of treatment plans. This could also enable physicians at hospitals without proton capabilities to make a betterinformed referral decision or aid patient selection.
Modern radiation treatments deliver highly conformal dose to the target. As a result, the falloff isodose lines typically resemble uniform expansions of the planning target volume. We propose to predict isodose lines based on target contour and thus predict dosevolume V D , thereby allowing V D and metrics of plan quality to be derived from contours before any plan is generated.
The treatment of breast cancer is a relatively new application of proton therapy (PT). 1 While recent comparative treatment planning studies of PT for breast cancer have highlighted the significant advantage in heart and lung sparing as well as in target coverage over traditional photon-based radiation techniques, 2, 3 for each individual case, it is not straightforward to determine the dose-volume metrics achievable with PT without generating a treatment plan. In this pilot study, we attempt to predict ipsilateral lung (IL) V 20 Gy(RBE) and V 5 Gy(RBE) based on the contours of each individual patient.
2 | ME TH ODS
2.A | Patient selection
Fifty-two randomly selected patients recently (2016-2017) treated for breast cancer in our clinic with uniform scanning (US) or pencil beam scanning (PBS) proton therapy were included in this study, which has been reviewed by our institutional review board. The diseases were left-sided for 36 patients, right-sided for 15, and bilateral for 1. Eighty percent of the patients had nodal involvement; and partial breast irradiation was not considered in this study. The prescription doses varied from 50.4 Gy(RBE) to 66.4 Gy(RBE).
2.B | Setup and delivery
Computed tomography (CT) scanning was performed for each patient at the simulation with the arms abducted above the head using a custom mold (Alpha Cradle, Smithers Medical Products, Inc., North Canton, OH, USA). Patients were immobilized in the supine position. There was no actual immobilization of the breast. The CTs were performed on a GE LightSpeed/Optima CT scanner.
The target delineation was described in our previous publication. 4 Although controversial in proton therapy, 5 the planning target volume (PTV) is still widely used by clinicians in evaluation of proton treatment plans (e.g., Ref. [4, 6, 7] ). There is also debate over the appropriate use of PTV margins for setup uncertainty and motion for breast cancer. We used a 7 mm margin medially and laterally but not posteriorly. In the distal/posterior direction, the plans were generated to cover the clinical target volumes and evaluated for range uncertainty. 8 In addition, we did not add the margin medially in the supraclavicular region to avoid extending the PTV into the esophagus. For complete review of the uncertainty margins and their application in US and PBS, refer to our recent book chapter. 9 Proton therapy was typically delivered with two anterior oblique en face fields. For US, due to the limitation in field size, matching fields were typically needed to cover the chest wall and supraclavicular nodes, with the match lines feathered. 4 
2.C | Dose prediction
We rescaled all the initial prescription doses to 50. Ten patients were randomly selected, for whom m was adjusted to minimize the root-mean-square error (RMSE) of prediction V(m)
where the chevron 〈 〉 denotes an average over patients. For each particular dose level D, patients were subsequently added to the cohort until the RMSE did not change significantly as the sample size further increased. That ensured the estimated prediction uncertainty be invariant under change of sample size; it also justified the sufficiency of the sample size of our study. The mean error,
was also tracked as a measure of systematic error of our prediction.
The patient treated for bilateral disease was considered as two cases, one left, and one right. By minimizing RMSE for the first ten patients, it was determined that V(11 mm) best estimated ipsilateral V 20 Gy(RBE) . The sample size increased to 16 to achieve convergence of RMSE, as shown in Fig. 3 . The RMSE for V 20 Gy(RBE) prediction converged to slightly less than 5%. The SE was −2%, indicating an insignificant (compared to the RMSE of 5%) systematic underestimation. The predicted and actual V 20 Gy(RBE) values for those 16 patients were plotted in Fig. 4 . The actual V 20 Gy(RBE) ranged from 6% to 23%. No statistically significant difference in V 20 Gy(RBE) was found between breast irradiation and chest wall irradiation (P = 0.8; two-sample ttest) or between left-side and right-side treatment (P = 0.9; twosample t-test).
| RESULTS
For the estimation of V 5 Gy(RBE) , m was determined to be 22 mm.
Convergence of RMSE to 6% was observed for the 52 patients 
| 55
Despite its simplicity, the model is effectively accounting for a number of patient-specific features in estimating dose-volume metrics. Since the prediction is derived directly from patient contours, the size of target and OARs (e.g., lung), the separation between target and OARs (e.g., thickness of rib cage), shapes, and/or curvatures are all implicitly considered in the model.
In our determination of the model parameter m, we increased the sample size until the convergence of prediction error was achieved (Fig. 3) . That means further increasing the sample size in establishing the model would not improve the prediction accuracy.
In other words, the currently observed prediction error is the intrin- uniform across the PTV surface. We effectively averaged the dose gradient around the entire PTV surface and summarized it into a single parameter m, disregarding the positional dependence of local dose gradient. However, there are certain clinical scenarios where dose conformality is compromised giving way to normal tissue sparing (e.g., heart, chest wall, rib). Those cases will inevitably become outliers for our model, one example of which is shown in Fig. 6 . In that case, part of the PTV is underdosed in order to spare the heart, which may be a common compromise one has to make in breast cases where internal mammary nodes are involved. As shown in the figure, the medial portion of PTV is touching the 20 Gy(RBE) isodose line, indicating a cold spot as low as 20 Gy(RBE), compared to the prescription dose of 50.4 Gy(RBE). Since that compromise was not accounted for in our model, the model overestimated the lung dose.
V 20 Gy(RBE) was predicted to be 18%, while the actual value was 13%. V 5 Gy(RBE) was also overestimated to be 39%, while the actual value was 32%.
The dose predictions are limited by the accuracy of dose calculation algorithm, especially in lung. Pencil beam (PB) algorithm was used in this study. 16 The deficiencies of PB algorithm have been reported in the literature for many years. [17] [18] [19] [20] [21] As commercial
Monte Carlo (MC) dose calculation algorithms recently became available, 22 , 23 the need for MC algorithm was demonstrated unequivocally for lung targets. 24 In a dosimetric comparison for ten lung cancer patients, it was shown that total lung V 20 Gy(RBE) maintained a 2% deviation across PB and MC, and similar trends were observed for V 10 Gy(RBE) and V 5 Gy(RBE). 25 For breast cancer, the clinical application of MC is still limited. The comparison of lung dose in breast treatment as computed with PB and MC warrants future investigation. As we started using MC for select cases of breast cancer, the differences in lung dose compared to US were likely within 5% and were certainly negligible compared to the interpatient anatomical variations.
The air gap may differ between US and PBS resulting changes in penumbra. On the one hand, the US range compensators are usually smaller due to a larger number of beams involved to cover the target. However, our US delivery is limited by the fixed gantry angles | 57
The intention of this study was to provide a patient-specific guideline dose for lung sparing, regardless of delivery technique.
Based on our analysis, there is no statistically significant difference in IL V 20 Gy(RBE) between US and PBS cases. In terms of the treatment planning process, high conformality is desired for both US and PBS plans. For our cohort, separate evaluation of the predicted IL V 20 Gy(RBE) for US and PBS, using the same parameter m, both yielded an RMSE of 5%. Thus, no systematic difference was observed in the prediction accuracy between US and PBS.
Of note, the high conformality achieved in our cases for the lowdose levels is indicative of one of the advantages of proton therapy for breast cancer patients: 5 Gy(RBE) is only~10% of prescription dose; yet the isodose line still conforms well to the PTV. It may not be the case for a different technique (e.g., parallel-opposed beams), in which only high-dose levels are conformed to the target.
Among the patients included in this study, 69% received boost radiation. While the boost dose was not considered in our model, it is our observation that boost radiation only increased the IL V 20 Gy(RBE) by 1%-2%, which is less than the RMSE of our prediction. For about one-third of the cohort, the initial prescription dose was 45 Gy(RBE) or 46 Gy(RBE).
The actual IL dose should be slightly smaller than our prediction because our model was based on a prescription of 50.4 Gy(RBE).
However, the difference in lung dose is not that significant. For example, for a prescription of 45 Gy(RBE), the expansion PTV + 11 mm would predict, instead of 20 Gy(RBE) isodose line, Fig. 2 ), again less than the RMSE of our model prediction. As a result, our model can be directly applied to all the common prescription dose levels, including sequential boost, while acknowledging the RMSE of 5%-6%.
A major portion of the cohort (80%) had nodal involvement, corresponding to a variety of target shapes on which our model was validated. None of the cases was partial breast irradiation, for which lung dose is usually not a clinical concern.
| CONCLUSION
To conclude, we have established a contour-based model that enable prediction of IL V 20 Gy(RBE) and V 5 Gy(RBE) for breast cancer patients treated with proton therapy. The model is clinically easy to implement and provides an estimate of the expected values prior to planning.
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